Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history.
Jabbour, E
Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history. [electronic resource] - Leukemia Jan 2010 - 6-12 p. digital
Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Review
1476-5551
10.1038/leu.2009.193 doi
Antineoplastic Agents--therapeutic use
Benzamides
Dasatinib
Drug Resistance, Neoplasm
Fusion Proteins, bcr-abl--genetics
Humans
Imatinib Mesylate
Leukemia, Myelogenous, Chronic, BCR-ABL Positive--drug therapy
Mutation
Piperazines--adverse effects
Protein Kinase Inhibitors--therapeutic use
Pyrimidines--adverse effects
Thiazoles--therapeutic use
Choosing the best treatment strategy for chronic myeloid leukemia patients resistant to imatinib: weighing the efficacy and safety of individual drugs with BCR-ABL mutations and patient history. [electronic resource] - Leukemia Jan 2010 - 6-12 p. digital
Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Review
1476-5551
10.1038/leu.2009.193 doi
Antineoplastic Agents--therapeutic use
Benzamides
Dasatinib
Drug Resistance, Neoplasm
Fusion Proteins, bcr-abl--genetics
Humans
Imatinib Mesylate
Leukemia, Myelogenous, Chronic, BCR-ABL Positive--drug therapy
Mutation
Piperazines--adverse effects
Protein Kinase Inhibitors--therapeutic use
Pyrimidines--adverse effects
Thiazoles--therapeutic use